Improving Prenatal Care to Reduce Early Onset Preeclampsia in Low-Income
Part of paid clinical trials in Kansas City, Kansas.
- Sponsor
- University of Kansas Medical Center
- Study ID
- NCT07491510
- Status
- Enrolling By Invitation
Conditions
- Aspirin Prophylaxis
- Monitoring Blood Pressure
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - 45 Years
- Healthy Volunteers
- Accepted
Interventions
- Active Comparator: Behavioral: Experimental: Centering HER (routine prenatal care + 7 doula-led 90-minute virtual group — BEHAVIORALroutine prenatal care + 7 doula-led 90-minute virtual group sessions with OB/GYN fellow oversight + Bluetooth BP cuff/scale ± Apple Watch
Study Details
The goal of this clinical trial is to learn if a telehealth hypertension group prenatal care program (Centering HER / HGPC-T) can improve blood pressure monitoring and aspirin adherence and help reduce early-onset preeclampsia in low-income, predominantly Black pregnant participants in Kansas who are \<13 weeks gestation, age ≥18, and moderate or high risk for preeclampsia (USPSTF). The main question\[s\] it aims to answer \[is/are\]: Does Centering HER increase hypertension monitoring and aspirin compliance compared with usual doula care? Is Centering HER feasible and acceptable, and what contextual factors influence implementation in community clinics?
Key Dates
- Start date
- Aug 1, 2025
- Status verified
- Jun 2026
- Primary completion
- Jun 30, 2026
- Completion
- Sep 30, 2026
Study Design
- Enrollment
- 36 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- FACTORIAL
- Primary purpose
- PREVENTION
Arms
- Placebo Comparator: usual doula care + routine prenatal care
- Active Comparator: Behavioral: Experimental: Centering HER (routine prenatal care + 7 doula-led 90-minute virtual grouproutine prenatal care + 7 doula-led 90-minute virtual group sessions with OB/GYN fellow oversight + Bluetooth BP cuff/scale ± Apple Watch
Primary Outcome Measure
mean diastolic blood pressure [ Time Frame: From enrollment to the end of treatment at 12 weeks ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Kansas Medical Center | Kansas City | Kansas | 66101 | - |
Find similar trials in Kansas City, KS
Related Studies
- Clinician Notification to Increase Aspirin Prophylaxis for Preeclampsia PreventionNot Yet Recruiting · Massachusetts General Hospital · Boston, Massachusetts